Novartis Sues Alvogen To Block Generic Dementia Patch

Law360, New York (January 7, 2013, 7:54 PM EST) -- Novartis AG slapped generic-drug maker Alvogen Group Inc. with a lawsuit in Delaware on Friday, accusing Alvogen of infringing two patents by seeking U.S. regulatory approval to make and sell generic versions of the Exelon patch, a dementia treatment.

Patent co-owners Novartis and LTS Lohmann Therapie-Systeme AG targeted Alvogen and a Pine Brook, N.J.-based Alvogen subsidiary, asking the court to rule that Alvogen had infringed the patent-in-suit and order that the approval of Alvogen's bid for approval of its proposed rivastigmine transdermal products can't come before...
To view the full article, register now.